Full Text | PDF

J Cancer 2017; 8(14):2765-2773. doi:10.7150/jca.19515 This issue Cite

Research Paper

Refining the American Joint Committee on Cancer Staging Scheme For Resectable Pancreatic Ductal Adenocarcinoma Using Recursive Partitioning Analysis

Yiquan Jiang^1*, Yanhong Su^2*, Yutong Chen^2*, Zhiyong Li^3✉

1. Department of Hepatobiliary and Pancreatic Surgery, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou 510060, China;
2. Department of Medical Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou 510060, China;
3. Department of Urology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou 510060, China.
* These authors contributed equally as first authors.

✉ Corresponding author: Zhiyong Li, 651 Dong Feng Road East, Guangzhou 510060, China; Tel and Fax: +86-20-8734 3088; E-mail: lizhiyorg.cn.

Abstract

Purpose: It remains unclear whether the recently proposed 8^th edition of the American Joint Committee on Cancer (AJCC) staging scheme for pancreatic ductal adenocarcinoma (PDAC) outperforms the 7^th edition. We assessed the prognostic performance of both these schemes and performed recursive partitioning analysis (RPA) to objectively regroup the 7^th and 8^th AJCC stages and derive a refined staging scheme.

Methods: We examined 8542 patients with resectable PDAC from the 2004-2012 Surveillance, Epidemiology, and End Results database. The dataset was randomly divided into training and validation sets. The performance of different staging schemes was evaluated in terms of prognostic stratification, discriminatory ability, and prognostic homogeneity.

Results: The 7^th and 8^th T classifications showed prominent heterogeneity within each subcategory when assessed against each other in the case of node-negative disease. RPA divided resectable PDAC into RPA-IA (8^th T1N0 limited to the pancreas), RPA-IB (8^th T1N0 extending beyond the pancreas, or 8^th T2-T3N0 limited to the pancreas), RPA-IIA (8^th T2N0 extending beyond the pancreas, or 8^th T1N1-N2), RPA-IIB (8^th T3N0 extending beyond the pancreas, or 8^th T2-T3N1), and RPA-III stages (8^th T2-T3N2) (median survival in the training set: 47, 28, 20, 16, and 14 months, respectively; P < 0.001). The RPA staging scheme outperformed the 7^th and 8^th AJCC classifications in terms of prognostic stratification, discriminatory ability, and prognostic homogeneity for both the training and validation sets.

Conclusions: The proposed RPA staging is a superior risk-stratified tool to the 7^th and 8^th AJCC classifications and is not substantially more complex.

Keywords: pancreatic ductal adenocarcinoma (PDAC), American Joint Committee on Cancer staging (AJCC), Surveillance, Epidemiology, and End Results (SEER), staging, survival.

Citation styles

©2024 Ivyspring International Publisher. Terms of use